ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 551

Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis

Craig Wiesenhutter, Coeur d'Alene Arthritis Clinic, Coeur D Alene, ID; University of Washington School of Family Medicine, Seattle, ID

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: biomarkers and treatment, Disease Activity, Doppler ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Treating rheumatoid arthritis (RA) patients to target (T2T) has been shown to result in better outcomes in patients with relatively recent onset RA. The implementation of this method requires performing disease activity measures (DAMs) with the disease activity score in 28 joints (DAS28) being the most commonly used. The use of clinically based DAMs in patients with longstanding RA is problematic as structural damage, and other comorbidities can lead to elevated scores because of the impact on composite elements not related to inflammation i.e. patient global and tender joint count. Including additional DAMs, such as a power Doppler joint count (UPD) and multibiomarker disease activity (MBDA) could possibly lead to better assessment of this patient population. The purpose of this abstract is to determine the changes in these three diverse DAMs and the relationships of these changes following the initiation of specific treatment modalities in patient with longstanding RA.

Methods: Patients at a community based rheumatology clinic undergo DAM assessments on a routine basis as part of the implementation of a T2T strategy. These assessments include the DAS28CRP, a UPD, and the MBDA. The UPD includes scoring at six dorsal wrist and six dorsal MCP sites. Patients underwent assessments prior to change in therapy, and then generally about six months later. Patients who were on biologics and found to be under inadequate control, had their biologic discontinued and the new therapy added later, depending on the half-life of the discontinued medication. The average duration of RA in patients at this clinic is > 10 years. The average DAS28CRP 4.18 +/- 1.32, average MBDA 41.4 +/- 14, and the average UPD 7.8 +/- 4.3.

Results:

N

Δ DAS28CRP AVG

SD

Prob

Δ MBDA AVG

SD

Prob

Δ UPD AVG

SD

Prob

DAS28CRP Vs MBDA

UPD Vs MBDA

DAS28CRP Vs UPD

MTX/Leflunomide

10

-1.63

0.83

0.00002

-12.4

8.0

0.00025

-3.2

2.8

0.003

r = 0.510*

r = 0.325

r = 0.425

Anti-TNFs

16

-0.94

1.24

0.0029

-11.5

11.8

0.007

-3.0

3.8

0.003

r = 0.454*

r = 0.488*

r = 0.573*

Tocilizumab

12

-1.44

1.13

0.0004

+6.3

11.4

0.044

-4.5

3.3

0.001

r = -0.252

r =-0.148

r = 0.277

Abatacept

10

-0.88

2.04

0.08

-2.5

10.8

0.24

-5

6.6

0.02

r =0.341

r =-0.736*

r = 0.619*

 Tofacitinib

11

-1.27

1.03

0.001

-11.3

13

0.035

-2.2

2.6

0.01

r =0.209

r =-0.707*

r = 0.565*

*P value < 0.05

Conclusion: Changes in diverse DAMs have moderate to high correlations following the initiation of specific therapy with most treatment modalities utilized in the management of longstanding RA. Tocilizumab did not have a positive correlation between DAS and the MBDA, which has been previously reported, and is presumed to be secondary to its mode of action which leads to significant elevation of IL-6 in the serum. Tofacitinib, a Jak-1 inhibitor, did not have a significant correlation between DAS and the MBNA, which has also been reported recently for another Jak-1 inhibitor in development, but had significant correlation with UPD and the MBNA in this study. This data suggest the validity of adding more diverse DAMs, such as UPD, and MBDA to clinical measures, such as the DAS28CRP, as endpoints in the implementation of a T2T strategy in the management of longstanding RA.


Disclosure: C. Wiesenhutter, None;

To cite this abstract in AMA style:

Wiesenhutter C. Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/changes-in-diverse-disease-activity-measures-are-highly-correlated-following-the-initiation-of-most-treatment-modalities-in-the-management-of-longstanding-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-diverse-disease-activity-measures-are-highly-correlated-following-the-initiation-of-most-treatment-modalities-in-the-management-of-longstanding-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology